[go: up one dir, main page]

MX2024001696A - Vacunas contra el virus de la enfermedad hemorragica del conejo (rhdv). - Google Patents

Vacunas contra el virus de la enfermedad hemorragica del conejo (rhdv).

Info

Publication number
MX2024001696A
MX2024001696A MX2024001696A MX2024001696A MX2024001696A MX 2024001696 A MX2024001696 A MX 2024001696A MX 2024001696 A MX2024001696 A MX 2024001696A MX 2024001696 A MX2024001696 A MX 2024001696A MX 2024001696 A MX2024001696 A MX 2024001696A
Authority
MX
Mexico
Prior art keywords
rhdv
disease virus
vaccines
antigens
hemorrhagic disease
Prior art date
Application number
MX2024001696A
Other languages
English (en)
Inventor
Alan John Young
Original Assignee
VST LLC dba Medgene Labs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VST LLC dba Medgene Labs filed Critical VST LLC dba Medgene Labs
Publication of MX2024001696A publication Critical patent/MX2024001696A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención describe composiciones inmunogénicas que contienen polipéptidos inmunogénicos del virus de la enfermedad hemorrágica del conejo (RHDV), incluyendo composiciones inmunogénicas que contienen antígenos que no son antígenos del RHDV, incluyendo antígenos que pueden usarse en la inmunización contra patógenos que causan enfermedades diarreicas. También se describen métodos para provocar una respuesta inmune con las composiciones inmunogénicas como las descritas, y métodos para tratar una infección por RHDV.
MX2024001696A 2021-08-05 2022-08-05 Vacunas contra el virus de la enfermedad hemorragica del conejo (rhdv). MX2024001696A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163229853P 2021-08-05 2021-08-05
PCT/US2022/039595 WO2023014983A2 (en) 2021-08-05 2022-08-05 Rabbit haemorrhagic disease virus (rhdv) vaccines

Publications (1)

Publication Number Publication Date
MX2024001696A true MX2024001696A (es) 2024-03-25

Family

ID=85154740

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024001696A MX2024001696A (es) 2021-08-05 2022-08-05 Vacunas contra el virus de la enfermedad hemorragica del conejo (rhdv).

Country Status (6)

Country Link
US (1) US20230192776A1 (es)
EP (1) EP4380953A4 (es)
AU (1) AU2022324480A1 (es)
CA (1) CA3228313A1 (es)
MX (1) MX2024001696A (es)
WO (1) WO2023014983A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024170516A1 (en) * 2023-02-13 2024-08-22 Hipra Scientific, S.L.U. Rabbit hemorrhagic disease virus vaccine and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989561A (en) * 1991-03-07 1999-11-23 Virogenetics Corporation Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
PL205229B1 (pl) * 2005-07-08 2010-03-31 Panstwowy Inst Weterynaryjny P Sposób wytwarzania rekombinowanej szczepionki przeciwko krwotocznej chorobie królików, szczepionka oraz zastosowanie antygenu rekombinowanego białka do wytwarzania szczepionki
ES2612854T3 (es) * 2012-06-12 2017-05-19 Alternative Gene Expression, S.L. Elementos de ADN recombinante para la expresión de proteínas recombinantes en una célula huésped
JP6063563B2 (ja) * 2012-06-12 2017-01-18 オルタナティブ ジーン エクスプレッション エセ．エレ． 宿主昆虫における組換えタンパク質の発現のためのバキュロウイルスｄｎａエレメント
HUE059211T2 (hu) * 2018-06-20 2022-10-28 Fatro Spa Vakcinák vérzéses nyúlbetegség megelõzésére

Also Published As

Publication number Publication date
US20230192776A1 (en) 2023-06-22
CA3228313A1 (en) 2023-02-09
WO2023014983A2 (en) 2023-02-09
WO2023014983A3 (en) 2023-04-06
EP4380953A2 (en) 2024-06-12
AU2022324480A1 (en) 2024-02-15
EP4380953A4 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
ZA202306479B (en) African swine fever (asf) virus vaccines
BR112022001185A2 (pt) Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
MX2022009989A (es) Composiciones inmunogenicas y vacunas para covid-19 vectorizadas por sarampion.
AR127585A1 (es) Vacuna de arn de virus sincicial respiratorio
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
AR109538A1 (es) Vacuna contra la gripe porcina
WO2017156511A8 (en) Live attenuated zika virus vaccine
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
ZA202310663B (en) Immunogenic compositions to treat and prevent microbial infections
MX2024001696A (es) Vacunas contra el virus de la enfermedad hemorragica del conejo (rhdv).
PH12018500305B1 (en) Multivalent vlp conjugates
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
BR112022003698A2 (pt) Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
PH12020500194A1 (en) Malaria vaccine
MX2024000138A (es) Vacunas contra el sapovirus.
BR112022007474A2 (pt) Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma